Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1828 - Detection of epidermal growth factor receptor mutations in circulating cell-free DNA versus tumor biopsy


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Targeted Therapy;  Non-Small Cell Lung Cancer


In-Jae Oh


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


I. Oh1, H. Seo1, H. Cho1, C. Park1, J. Lim1, Y. Kim1, Y. Choi2

Author affiliations

  • 1 Department Of Internal Medicine, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, 58128 - Hwasun/KR
  • 2 Department Of Pathology, Chonnam National University Medical School, 58128 - Hwasun/KR


Abstract 1828


Epidermal growth factor receptor (EGFR) mutations are predictive marker of EGFR-tyrosine kinase inhibitor (TKI) therapy. We compared the sensitivity of EGFR mutation detection techniques between matched tumor tissue and peripheral blood sample in patients with lung adenocarcinoma.


We collected the paired samples from plasma and paraffin-embedded tumor tissue in 295 patients before EGFR-TKIs therapy. DNA extraction was performed using the QIAamp MinElute virus spin kit and EGFR mutation analysis was done by two detection methods. One is the PNAClamp™ (Clamp) which is the PNA-based PCR clamping that selectively amplifies only the mutated target DNA sequence as minor portion in mixture with the major wild type DNA sequences. The other is the PANAMutyper EGFR kit (Mutyper), which use PNA clamping-assisted fluorescence melting curve analysis to perform mutation detection and genotyping.


In tissue samples, the positive rates of EGFR sensitive mutation were not different between two methods (26.8% in Mutyper vs. 24.7% in Clamp). Plasma sensitivity was significantly higher in Mutyper than Clamp (70.9% vs. 30.1%, p 


The plasma sensitivity and concordance of Mutyper were better than Clamp test. And Mutyper could better predict the PFS of EGFR mutation in plasma. So this technique is expected to be useful to detect EGFR mutation in circulating cell-free DNA sample.

Clinical trial identification

Legal entity responsible for the study



This research was financially supported by grants from the Panagene Inc.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.